These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 8364926

  • 1. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1993 Sep 15; 53(18):4315-21. PubMed ID: 8364926
    [Abstract] [Full Text] [Related]

  • 2. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 3. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1994 May 15; 54(10):2744-50. PubMed ID: 8168105
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 10. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S.
    Cancer Res; 2001 Mar 01; 61(5):2031-7. PubMed ID: 11280763
    [Abstract] [Full Text] [Related]

  • 11. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 12. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY, Chou T, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):295-304. PubMed ID: 2953816
    [Abstract] [Full Text] [Related]

  • 13. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K, Chang AE, Shu SY.
    Cancer Res; 1990 Jul 15; 50(14):4371-6. PubMed ID: 2114215
    [Abstract] [Full Text] [Related]

  • 14. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S.
    Cancer Res; 1996 Oct 01; 56(19):4338-42. PubMed ID: 8813119
    [Abstract] [Full Text] [Related]

  • 15. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H, Shu S.
    J Immunol; 1998 Apr 01; 160(7):3444-52. PubMed ID: 9531305
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM, Blazar BR, Bach FH, Ochoa AC.
    J Immunol; 1989 Feb 15; 142(4):1383-94. PubMed ID: 2521662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.